Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003603695 | SCV004532909 | uncertain significance | Brugada syndrome 7 | 2023-01-09 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant has not been reported in the literature in individuals affected with SCN3B-related conditions. This variant is present in population databases (rs758655363, gnomAD 0.0009%). This sequence change replaces asparagine, which is neutral and polar, with aspartic acid, which is acidic and polar, at codon 5 of the SCN3B protein (p.Asn5Asp). |
Ambry Genetics | RCV004374202 | SCV004944248 | uncertain significance | Cardiovascular phenotype | 2024-01-03 | criteria provided, single submitter | clinical testing | The c.13A>G (p.N5D) alteration is located in exon 1 (coding exon 1) of the SCN3B gene. This alteration results from a A to G substitution at nucleotide position 13, causing the asparagine (N) at amino acid position 5 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |